Table 1.
Anthropometric traits and clinical biochemistry of DMT2 patients.
| Variable | Metformin n = 59 (57.3%) |
Metformin + Glibenclamide n = 44 (42.7%) |
p = |
|---|---|---|---|
| Age (years) | 55.8 ± 10.83 | 53.11 ± 11.28 | 0.225 t |
| Weight (Kg) | 78.83 ± 16.73 | 71.72 ± 13.39 | 0.022 *,t |
| Sex “n” (%) Female |
42 (71.2%) |
31 (70.5%) |
0.936 Xi |
| Male | 17 (28.8 %) | 13 (29.5%) | |
| Treatment period (years) |
3 (1.25–7.5) | 7.5 (3–14.5) | <0.001 *,U |
| BMI | 31.92 ± 6.29 | 29.23 ± 4.81 | 0.020 *,t |
| Normal weight Overweight Obesity type I II III |
4 (6.8%) 20 (33.9%) 18 (30.5%) 12 (20.3%) 5 (8.5%) |
7 (15.9%) 19 (43.2%) 8 (18.2%) 8 (18.2%) 2 (4.5%) |
0.074 U |
| Metformin plasmatic concentration ng/mL |
290.75 (107.69–815.02) |
570.91 (170.58–1043.33) |
0.203 U |
| Glucose mg/dL | 115.5 (102–157) | 192.5 (139–238.5) | <0.001 *,U |
| HbA1c % | 6.4 (5.9–7.3) | 9.05 (7.55–10.9) | <0.001 *,U |
| control | 43 (72.9%) | 5 (11.4%) | <0.001 *,Xi |
| non-control | 16 (27.1%) | 39 (88.6%) | |
| Total cholesterol mg/dL | 175.05 ± 39.46 | 182.1 ± 33.78 | 0.360 t |
| control | 41 (70.7%) | 27 (67.5%) | 0.736 Xi |
| non-control | 17 (29.3%) | 13 (32.5%) | |
| LDL cholesterol mg/dL | 91.41 ± 32.43 | 103.69 ± 29.89 | 0.105 t |
| HDL cholesterol mg/dL | 41 (34.55–45.75) | 41.5 (36.8–47.2) | 0.806 U |
| Triglycerides mg/dL | 194 (131–223.5) | 157 (131–252) | 0.925 U |
| control | 16 (29.1%) | 17 (44.7%) | 0.121 Xi |
| non-control | 39 (70.9%) | 21 (55.3%) | |
| Glomerular filtration rate (MDRD-4) | 93.4 (87.81–115.16) | 103.4 (89.23–131.7) | 0.329 U |
| Metformin dose mg/day | 1700 (850–1700) | 2125 (1700–2550) | 0.001 *,U |
| Daily metformin dose mg/kg/day | 19.25 (11.92–25.84) | 29.2 (21.55–34.21) | <0.001 *,U |
Variables with normal distribution are presented as mean ± standard deviation; variables with non-normal distribution are presented as median; interquartile range 25–75%; t Student’s “t” test; U Mann Whitney’s U test; Xi Pearson’s Chi-square test; * statistical significance (p < 0.05).